By the Committee on Health Care Standards & Regulatory Reform and Representative D. Prewitt

1 A bill to be entitled An act relating to pharmaceuticals; creating a 2 3 study commission for the purpose of studying the variations in the cost of prescription 4 drugs; providing for membership; providing for 5 organization and administration; requiring 6 7 meetings and public hearings; providing for 8 expert testimony; requiring a report; providing 9 an effective date. 10 Be It Enacted by the Legislature of the State of Florida: 11 12 13 Section 1. Prescription Drug Policy Review 14 Commission. --15 (1) There is hereby created an independent study commission, designated as the Prescription Drug Policy Review 16 17 Commission. The commission shall consist of 30 members, as 18 follows: 19 One member of the House of Representatives 20 appointed by the Speaker of the House of Representatives. 21 Two members of the Senate appointed by the (b) 22 President of the Senate. 23 The Director of Health Care Administration or a designee. 24 The State Health Officer or a designee. 25 (d) 26 (e) The Secretary of Business and Professional 27 Regulation or a designee. 28 (f) Twenty-four members appointed by the Governor, as 29 follows: 30 Two members representing the Florida Pharmacy Association who are practicing pharmacists.

1	2. One member representing the Florida Podiatric
2	Medical Association.
3	3. One member representing the Florida Optometric
4	Association.
5	4. One member representing independent pharmacies.
6	5. One member representing the Florida Retail
7	Federation who is engaged in retail pharmacy.
8	6. One member representing high-volume chain
9	pharmacies.
10	7. One member representing the Florida Academy of
11	Family Physicians.
12	8. One member representing the Florida Nurses
13	Association.
14	9. One member representing the Florida Osteopathic
15	Medical Association.
16	10. One member representing the Florida Medical
17	Association.
18	11. One member representing pharmaceutical
19	manufacturers.
20	12. Two consumer members, one of whom is 60 years of
21	age or older.
22	13. One member representing the Florida Association of
23	Wholesale Druggists.
24	14. One member from each of the following hospital
25	associations: the Florida League of Health Systems, the
26	Association of Community Hospitals and Health Systems of
27	Florida, and the Florida Hospital Association.
28	15. One nursing home consulting pharmacist.
29	16. One member representing the Florida Hospices,
30	Inc., with knowledge of acquired immune deficiency syndrome
31	and acquired immune deficiency syndrome medication delivery.

- $\underline{\mbox{17.}}$  One member representing the Florida Association of Health Maintenance Organizations.
- 18. Two members representing pharmaceutical manufacturers, one of whom shall be a representative of the Generic Pharmaceutical Industry Association.
- 19. One member representing direct mail order providers.

One of the medical professional members shall have a speciality in geriatric medicine.

- among the commission members and shall not be an agency head or the designee of an agency head. The commission is assigned to the Agency for Health Care Administration for administrative purposes only. The agency shall provide staff and technical assistance to the commission. The commission shall meet as soon as possible after July 1, 1997, and may elect a vice chair and such other officers as may be deemed necessary by the commission.
- (3) Commission members shall serve without compensation. Travel costs for commission members shall be paid by the commission member or by the organization to which the commission member belongs.
- (4)(a) The commission shall hold at least four public hearings, geographically spread equally around the state, for the purpose of hearing testimony and studying the variations in the cost of prescription drugs, both domestic and foreign. The study shall include manufacturer, wholesale, and retail prescription drug pricing, including the costs, fees, and time involved in providing, dispensing, consulting, and delivering services to institutions and for retail sales; review of

federal and other states' policies and regulations regarding 1 prescription drug prices; and an assessment of the potential 2 impact of regulatory and market forces, including the "managed 3 4 care" effect of federal and state "health care reform" on 5 prescription drug pricing. 6 (b) The commission may also hear testimony from 7 experts in the fields of health care cost containment, 8 pharmacy practice, and pharmaceutical manufacturing and sales, 9 and from health care providers and practitioners, officials representing state agencies or the Federal Government, and 10 such other persons as deemed necessary by the commission for 11 12 the accomplishment of its duties. 13 (5) No later than June 1, 1998, the commission shall submit a report of its findings and recommendations to the 14 15 Governor, the Speaker of the House of Representatives, the President of the Senate, the House and Senate minority 16 leaders, and the chairs of the appropriate substantive 17 18 committees of the House and Senate. 19 Section 2. This act shall take effect upon becoming a 20 law. 21 22 23 HOUSE SUMMARY Creates the Prescription Drug Policy Review Commission to study the variations in the cost of prescription drugs in the state. Provides for commission membership, organization, administration, meetings, public hearings, and expert testimony. Requires a report to the Governor and Legislature. 24 25 26 27 2.8 29 30 31